Loading...
Market
What will be the market response to Elevidys gene therapy by end of 2024?
2
Resolution / Starting Odds
Positive • 33%
Neutral • 33%
Negative • 34%
Industry analysts' reports and stock market data
Story
Sarepta's Elevidys Gene Therapy Approved by FDA Despite Staff Opposition; BofA Raises Price Objective to $213
Jun 20, 2024, 09:49 PM
Sarepta Therapeutics (SRPT) has received full approval from the FDA for its gene therapy, Elevidys, despite opposition from the review staff. The decision was made by CBER Director Peter Marks, who overruled the recommendations for a complete response letter (CRL) from the FDA's Office of Tissues and Advanced Therapies (OTP) directors Lola Fashoyin-Aje and Nicole Verdun. This approval is seen as a significant boost for Sarepta, with BofA raising its price objective from $166 to $213. The decision has sparked discussions about the FDA's regulatory approach, particularly in the context of recent challenges in the Duchenne muscular dystrophy (DMD) space. Sarepta also saw early buyers of 500 June 28th $120/$155 call spreads for $14.60.
View original story
Similar markets
Yes • 33%
No • 34%
Top 3 but not best-selling • 33%
Less than $500 million • 33%
$500 million to $1 billion • 34%
More than $1 billion • 33%
Stock price up 0-10% • 33%
Stock price up 10-20% • 33%
Stock price up more than 20% • 34%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%
Less than 100 • 33%
100 to 500 • 34%
More than 500 • 33%
Less than 5 • 33%
5 to 10 • 34%
More than 10 • 33%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million - $700 million • 25%
$700 million - $900 million • 25%
More than $900 million • 25%
Less than 20% • 33%
20-40% • 33%
More than 40% • 33%